These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16078216)

  • 1. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
    Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
    Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?
    Dressler D; Münchau A; Bhatia KP; Quinn NP; Bigalke H
    Eur Neurol; 2002; 47(2):118-21. PubMed ID: 11844901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay.
    Dressler D; Dirnberger G
    Eur Neurol; 2001; 45(4):257-60. PubMed ID: 11385265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials.
    Chinnapongse RB; Lew MF; Ferreira JJ; Gullo KL; Nemeth PR; Zhang Y
    Clin Neuropharmacol; 2012; 35(5):215-23. PubMed ID: 22932474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.
    Dressler D; Rothwell JC; Bhatia K; Kopp B; Bigalke H; Adib Saberi F
    J Neurol; 2023 Mar; 270(3):1524-1530. PubMed ID: 36434127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin for treatment of dystonia.
    Dressler D
    Eur J Neurol; 2010 Jul; 17 Suppl 1():88-96. PubMed ID: 20590814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.
    Jankovic J; Hunter C; Dolimbek BZ; Dolimbek GS; Adler CH; Brashear A; Comella CL; Gordon M; Riley DE; Sethi K; Singer C; Stacy M; Tarsy D; Atassi MZ
    Neurology; 2006 Dec; 67(12):2233-5. PubMed ID: 17190952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
    Dressler D; Hallett M
    Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
    Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):601-7. PubMed ID: 7500097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.
    Göschel H; Wohlfarth K; Frevert J; Dengler R; Bigalke H
    Exp Neurol; 1997 Sep; 147(1):96-102. PubMed ID: 9294406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.